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Abstract: Carnosine affords protection against oxidative and carbonyl stress, yet high concentrations
of the carnosinase-1 enzyme may limit this. We recently reported that high urinary carnosinase-1 is
associated with kidney function decline and albuminuria in patients with chronic kidney disease.
We prospectively investigated whether urinary carnosinase-1 is associated with a high risk for de-
velopment of late graft failure in kidney transplant recipients (KTRs). Carnosine and carnosinase-1
were measured in 24 h urine in a longitudinal cohort of 703 stable KTRs and 257 healthy controls.
Cox regression was used to analyze the prospective data. Urinary carnosine excretions were signifi-
cantly decreased in KTRs (26.5 [IQR 21.4–33.3] µmol/24 h versus 34.8 [IQR 25.6–46.8] µmol/24 h;
p < 0.001). In KTRs, high urinary carnosinase-1 concentrations were associated with increased risk of
undetectable urinary carnosine (OR 1.24, 95%CI [1.06–1.45]; p = 0.007). During median follow-up
for 5.3 [4.5–6.0] years, 84 (12%) KTRs developed graft failure. In Cox regression analyses, high
urinary carnosinase-1 excretions were associated with increased risk of graft failure (HR 1.73, 95%CI
[1.44–2.08]; p < 0.001) independent of potential confounders. Since urinary carnosine is depleted and
urinary carnosinase-1 imparts a higher risk for graft failure in KTRs, future studies determining the
potential of carnosine supplementation in these patients are warranted.
Keywords: carnosine; carnosinase-1; kidney transplantation; oxidative stress; graft failure
1. Introduction
Kidney transplantation is the treatment of choice in patients with end stage renal
disease. Compared to treatment by dialysis, it reduces mortality, is cost effective, and
increases quality-adjusted life years [1–4]. However, despite significant progress in im-
munosuppression and supportive treatment, half of kidney recipients still experience graft
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failure or die within a decade after transplantation [5]. Thus, identification of patients at
risk of early graft failure is decisive in improving graft survival rate. Even though a kidney
biopsy is the gold standard for the diagnosis of graft rejection, identification of potentially
modifiable risk factors for predicting risk of graft failure might help to improve long-term
graft survival.
We and others have previously reported that a polymorphism in the CNDP1 gene,
encoding serum carnosinase-1 (CN1), is associated with lower risk of developing diabetic
nephropathy in patients with type 2 diabetes [6–10]. Additionally, in a prospective study
of pediatric patients with non-diabetic nephropathies, the CNDP1 polymorphism was
found to correlate with renal survival, particularly in patients with glomerulopathies [11].
Although these studies provide compelling evidence for a protective role of CNDP1 in
renal disease, other studies have failed to replicate these findings [12,13]. Yet, based on the
available in vitro and in vivo evidence, the current hypothesis on the role of CN1 in kidney
disease puts forward that low serum CN1 concentrations and low enzymatic activity will
promote high tissue carnosine concentrations. As carnosine and other histidine-containing
dipeptides (HCDs) are endowed with reno-protective properties in the setting of oxidative
and glycative stress [6,14], depletion of such HCDs will render the kidney tissue more
vulnerable to hyperglycemia or other diseases in which oxidative stress prevails.
The plausibility that CN1 may have a negative effect on the progression of kidney
disease is further substantiated by in vivo studies showing that overexpression of CN1
aggravates diabetic nephropathy and results in decreased plasma and kidney carnosine
levels [15–17]. In contrast, carnosine feeding in diabetic and non-diabetic animal models
decreases urinary markers of oxidative and carbonyl stress, reduces proteinuria, and
mitigates glomerular damage [15,18–20]. Of note, while circulating serum carnosine is
difficult to detect as a result of CN1 enzymatic activity, urinary carnosine, which may, to
some extent, be expected to reflect serum carnosine, appears to be an easier and reliable
estimation [20,21]. Indeed, in humans, urinary carnosine appeared to correlate positively
with serum carnosine, and inversely with serum CN1 concentrations [22].
We have recently reported that CN1 is detected in urine of healthy subjects and patients
with type 2 diabetes [23]. Our previous studies suggest that high urinary CN1 levels in
diabetic and non-diabetic patients with chronic kidney disease (CKD) are associated with
renal function decline and the degree of albuminuria [23,24].Whether high urinary CN1
results in low urinary carnosine is currently unknown. If so, it would suggest that urinary
CN1 indirectly correlates with the ability of the kidney to protect itself against oxidative
and carbonyl stress.
Interstitial fibrosis and tubular atrophy (IFTA) is a chronic, progressive, and irre-
versible histopathological entity that commonly occurs early after transplantation and
is the major cause of late allograft failure [25–27]. Oxidative stress is a main contributor
to IFTA [28] and is inevitably present in kidney transplant recipients (KTRs) during the
early period post-transplantation [29]. In keeping with the reno-protective properties of
carnosine and the role of CN1 in the progression of renal disease, the primary aim of this
study was to investigate the association of urinary CN1 excretion with graft failure in a
large cohort of stable KTRs. Secondly, we assessed whether urinary carnosine excretion
differs between KTRs and healthy subjects and, thirdly, whether urinary CN1 is inversely
associated with urinary carnosine.
2. Materials and Methods
2.1. Study Population
In this observational prospective study, adult KTRs (≥18 years old) who visited the
outpatient clinic of the University Medical Center Groningen between 2008 and 2011,
and with a functional graft of at least 1 year, were invited to participate (TransplantLines
Food and Nutrition Biobank and Cohort Study, Clinicaltrials.gov NCT02811835) [30,31].
Healthy kidney donors who participated in the screening program donation, and whose
biomaterials were collected prior to kidney donation, were included as a control group.
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All participants signed the informed consent. The study protocol was approved by the
institutional ethical review board (Medical Ethical Committee 2008/186) adhering to the
Declaration of Helsinki. Subjects with missing data on urinary CN1 were excluded, leaving
703 KTRs and 257 healthy subjects eligible for analyses.
2.2. Data Collection, Clinical and Laboratory Measurements
Baseline measurements were obtained during a morning visit at the outpatient clinic.
Subjects were instructed to collect 24 h urine and to fast overnight prior to the visit. Infor-
mation on patient’s health status, medication use, and medical history was obtained from
medical records. Body composition and hemodynamic parameters were measured accord-
ing to a strict standardized protocol [31]. Serum parameters including lipid, inflammation,
and glucose homeostasis were measured with spectrophotometric-based routine laboratory
methods (Roche Diagnostics, Rotkreuz, Switzerland). Urinary malondialdehyde (uMDA)
was measured by validated high-performance liquid chromatography on a Jasco system
(Jasco GmbH Deutschland, Gross-Umstadt, Germany) after derivatization of urine samples
with 2,4-dinitrophenylhydrazine (DNPH) using an ODS2 column (10 cm × 4.6 mm, 3 µm)
and a photodiode array detector. The mobile phase consisted of 0.2% acetic acid ( v/v) in
distilled water and acetonitrile (42:58, v/v). The method was validated in terms of linearity,
lower limit of quantification, lower limit of detection, precision, accuracy, recovery, and sta-
bility according to the U.S. Food and Drug Administration (FDA) guidelines [32]. Urinary
liver-type fatty acid-binding protein (uL-FABP) was measured by ELISA (human uL-FABP
assay kit 96 test; CMIC holdings Co, Japan) with a detection limit of 0.036 µg/L, intra-assay
variabilities of 3.8% and 2.5%, and inter-assay variabilities of 10.4% and 7.3% based on four
replicate measurements of urine samples with uL-FABP concentrations of 2 and 40 µg/L,
respectively [33].
Diabetes was diagnosed based on the American Diabetes Association criteria (2017) as
having fasting plasma glucose ≥ 7.0 mmol/L, or/and HbA1c ≥ 48 mmol/mol, or the use of
antidiabetic medication [34]. Kidney function was assessed by estimation of the glomerular
filtration rate (eGFR) based on the Chronic Kidney Disease Epidemiology Collaboration
equation with serum creatinine and cystatin C [35]. Proteinuria was diagnosed if total
urinary protein excretion was ≥0.5 g/24h. Delayed graft function was defined as oliguria
of >7 days, or the need for peritoneal dialysis or hemodialysis. Dietary intake was assessed
with a previously validated food frequency questionnaire (FFQ) [36], which inquired about
intakes of 177 food items during the past month, considering seasonal variations. Dietary
data were converted into daily nutrient intakes using the Dutch Food Composition Table
2006 [37]. Dietary intakes were adjusted for total energy intake (kcal/24 h) according to the
residual method [38]. In addition to the FFQ, protein intake was also estimated using the
Maroni equation [39]. Smoking behavior and alcohol consumption were assessed with a
separate questionnaire [40].
2.3. Assessment of Urinary CN1 and Urinary Carnosine
Urinary CN1 concentrations were measured by ELISA as previously described [23,24]
and can be found in detail in Appendix A (Appendix A.1, Carnosinase-1 Determination
in Urine by ELISA). Measurement of urinary carnosine concentrations was performed
as part of amino acid profiling with validated liquid chromatography isotope dilution
mass spectrometry and is described in detail in Appendix A (Appendix A.2, Amino Acid
Profiling with Liquid Chromatography Isotope Dilution Mass Spectrometry).
2.4. Clinical Endpoints
The primary endpoint of this study was death-censored graft failure, which was
defined as re-transplantation or return to dialysis. The surveillance system of the outpatient
clinic program ensured up-to-date information on KTR status with no loss to follow-up.
Endpoints were recorded until September 2015.
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2.5. Statistical Analyses
Data analyses were performed with SPSS 25.0 software (IBM Corporation) and R
software version 3.5.1 (R Foundation for Statistical Computing). Data are presented as
mean ± standard deviation (SD) for normally distributed data, median and interquartile
range (IQR) for skewed distributions, or absolute number and percentage for nominal data.
A two-sided p value < 0.05 was considered as statistically significant. Baseline differences
between KTRs and healthy kidney donors were assessed with an unpaired t-test, Mann–
Whitney U test, or chi-square test. A binary logarithmic (log2) transformation was applied
to urinary CN1 excretions, urinary CN1 concentrations, and urinary CN1/creatinine
ratios and used as such through the entire regression analysis. Logistic regression was
performed to assess the association of urinary CN1 concentration with urinary carnosine
with subsequent cumulative adjustment for sex, age, and eGFR. The associations of urinary
CN1 excretion with baseline characteristics of KTRs were studied by linear regression
with subsequent cumulative adjustment for age, sex, and eGFR. Regression coefficients are
presented as standardized beta values (St. β) referring to the number of SDs the dependent
variable changes per SD increase of the independent variable, allowing comparison of
different variables.
Prospective Analyses
Cox regression models were employed to investigate the association of urinary CN1
excretions, urinary CN1 concentrations, and urinary CN1/creatinine ratio with risk of
graft failure. The Cox regression models were built up in a stepwise fashion to keep the
number of predictors in proportion to the number of events. Adjustments were made
a priori and for relevant variables identified by linear regression if the p value for the
association with urinary CN1 excretion was <0.05. Crude associations (Model 1) were
cumulatively adjusted for basic confounders, i.e., age, sex, body mass index (Model 2),
and renal function, i.e., eGFR and proteinuria (Model 3). To prevent overfitting, Model 3
was additionally adjusted for cardiovascular risk factors (Model 4), transplantation-related
factors (Model 5), post-transplantation complications (Model 6), and urinary parameters
(Model 7). Cardiovascular risk factors were defined as systolic blood pressure, HDL
cholesterol, triglycerides, use of antihypertensive treatment, presence of diabetes, and
medical history of cardiovascular intervention. Transplantation factors were defined as
dialysis vintage, time from transplantation to study baseline, deceased donor, number
of transplantations up to baseline, and calcineurin inhibitor use. Post-transplantation
complications were defined as delayed graft function, graft rejection, and post-transplant
diabetes mellitus. The proportional hazard assumption was checked for urinary CN1
excretions, urinary CN1 concentrations, and urinary CN1/creatinine ratio. Potential
interactions of urinary CN1 with age, sex, BMI, eGFR, proteinuria, and urinary urea
excretions for the associations with graft failure were checked. To visualize the continuous
associations of urinary CN1 with the risk of graft failure, log2-transformed urinary CN1
excretion, urinary CN1 concentration, and urinary CN1/creatinine ratio were individually
plotted against the risk of graft failure.
3. Results
3.1. Urinary Carnosine is Reduced in KTRs Compared to Healthy Donors
We studied 703 stable KTRs (57% male; age 53 ± 13 years old) at a median time of
5.4 [IQR 1.9–12.0] years after transplantation, and 257 healthy kidney donors (44% male;
age 54 ± 11 years old). The characteristics of KTRs and healthy donors are depicted
in Table 1.
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Table 1. Baseline characteristics of KTRs compared to healthy subjects.
Variable
KTRs Healthy Subjects
n = 703 n = 257 p-Value
Urinary CN1
CN1 excretion, µg/24 h 29.4 [17.4–49.2] 32.7 [21.6–43.6] 0.42
CN1 concentration, µg/L 12.3 [8.1–20.9] 13 [10.5–16.5] 0.72
CN1/creatinine ratio, µg/mmol 2.7 [1.5–4.6] 2.6 [1.6–3.7] 0.09
Below detection limit (<4 µg/L), n (%) 95 (14) 33 (13) 0.76
Urinary carnosine
Carnosine excretion, µmol/24 h 26.5 [21.4–33.3] 34.8 [25.6–46.8] <0.001
Carnosine concentration, µmol/L 9.9 [9.9–11.5] 11.4 [9.9–19.5] <0.001
Carnosine/creatinine ratio, µmol/mmol 2.3 [1.8–3.2] 2.8 [2.1–3.8] <0.001
Below detection limit (<10 µmol/L), n (%) 465 (66) 96 (37) <0.001
Demographics
Male n, (%) 399 (57) 114 (44) 0.001
Age, years 53.0 ± 13 53.8 ± 11 0.34
Body composition
BMI, kg/m2 26.7 ± 4.8 26.0 ± 3.5 0.02
Waist circumference, cm 98 ± 15 91.3 ± 10.4 <0.001
Cardiovascular
Systolic blood pressure, mmHg 136 ± 17.5 127 ± 13.1 <0.001
Diastolic blood pressure, mmHg 83 ± 11 77 ± 9 <0.001
Mean arterial pressure, mmHg 107 ± 15 96 ± 16.1 <0.001
Heart rate, bpm 69 ± 12 67 ± 10 0.02
Lipids
Total cholesterol, mmol/L 5.1 ± 1.1 5.4 ± 1.0 0.002
HDL cholesterol, mmol/L 1.4 ± 0.5 1.6 ± 0.5 0.02
LDL cholesterol, mmol/L 3.0 ± 0.9 3.8 ± 1.0 <0.001
Triglycerides, mmol/L 1.7 [1.3–2.3] 1.2 [0.9–1.6] <0.001
Glucose homeostasis
Diabetes mellitus, n (%) 168 (24) 13 (5) <0.001
Glucose, mmol/L 5.3 [4.8–6.0] 5.3 [5.0–5.7] 0.22
HbA1c, mmol/mol 41.9 ± 8.9 37.6 ± 3.9 <0.001
Renal function
Serum creatinine, µmol/L 125 [99–160] 72 [64–81] <0.001
eGFR, ml/min/1.73 m2 45 ± 18 92 ± 16 <0.001
Creatinine clearance, ml/min 66 ± 27 127 ± 40 <0.001
Proteinuria, n (%) 157 (22) 1 (0.5) <0.001
Dietary intakes *
Energy intake, kcal/24 h 2170 ± 639 2295 ± 738 0.03
Total protein intake g/24 h 82 ± 12 85±13 0.01
Animal protein intake g/24 h 51 ± 13 52 ± 13 0.17
Total meat intake g/24 h 96 [74–116] 94 [72–115] 0.71
Red meat intake g/24 h 82 [59–103] 80 [60–106] 0.76
Serum parameters
NT-proBNP, ng/L 255 [108–625] 40 [23–68] <0.001
Sodium, mmol/L 141 ± 2.8 142 ± 2.0 <0.001
Potassium mmol/L 4.0 ± 0.5 3.9 ± 0.3 <0.001
hsCRP, mg/L 1.6 [0.7–4.6] 1.1 [0.6–2.3] <0.001
Urinary parameters
Urea excretion, mmol/24 h 384 [308–456] 392 [336–463] 0.09
Creatinine excretion, mmol/24 h 11.6 ± 3.5 13.3 ± 4.4 <0.001
Medication use
Antihypertensives, n (%) 620 (88) 29 (11) <0.001
Data are presented as mean ± SD, percentage, or median [IQR]. p value for statistical difference was tested by an independent t-test,
Mann–Whitney U test, or chi-squared test. * Dietary intakes were adjusted for energy intake according to the residual method. Data were
available for 640 KTRs and 173 healthy subjects. Abbreviations: BMI: body mass index, HDL: high-density lipoprotein, LDL: low-density
lipoprotein, eGFR: estimated glomerular filtration rate, NT-proBNP: N-terminal pro-brain natriuretic peptide, hsCRP: high-sensitivity
C reactive protein, h: hour.
Median urinary CN1 excretions were similar in KTRs and healthy donors (29.4
[17.4–49.2] µg/24 h versus 32.7 [21.6–43.6] µg/24 h; p = 0.42). Similarly, there were no dif-
ferences in median urinary CN1 concentrations and median urinary CN1/creatinine ratios
between the studied groups. KTRs with proteinuria had higher urinary CN1 excretions
in comparison to KTRs without proteinuria and to healthy subjects (data not shown). Of
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note, urinary CN1 was below the detection limit in 95 (14%) of KTRs compared to 33 (13%)
healthy donors (Table 1).
Data are presented as mean ± SD, percentage, or median [IQR]. p value for statistical
difference was tested by an independent t-test, Mann–Whitney U test, or chi-squared
test. * Dietary intakes were adjusted for energy intake according to the residual method.
Data were available for 640 KTRs and 173 healthy subjects. Abbreviations: BMI: body
mass index, HDL: high-density lipoprotein, LDL: low-density lipoprotein, eGFR: estimated
glomerular filtration rate, NT-proBNP: N-terminal pro-brain natriuretic peptide, hsCRP:
high-sensitivity C reactive protein, h: hour.
Interestingly, urinary carnosine excretion was significantly lower in KTRs
(26.5 [21.4–33.3] µmol/24 h versus 34.8 [25.6–46.8] µmol/24 h; p < 0.001) compared to the
healthy group. Likewise, urinary carnosine concentration and urinary carnosine/creatinine
ratios were lower in KTRs (all p < 0.001). In line with this, the proportion of subjects with
urinary carnosine below the detection limit was higher in the KTRs compared to healthy
controls (66% versus 37%; p < 0.001).
KTRs had a higher BMI in comparison to the healthy group. As anticipated, eGFR
was significantly lower in KTRs (45 ± 18 mL/min/1.73 m2 versus 92 ± 16 mL/min/1.73 m2;
p < 0.001). Accordingly, serum creatinine levels (125 [99–160]µmol/L versus 72 [64–81] µmol/L;
p < 0.001) and the proportion of subjects with proteinuria (22% versus 0.5%; p < 0.001) were
also significantly higher in KTRs. Additionally, systolic and diastolic blood pressures were
higher in KTRs. Furthermore, KTRs had higher levels of triglycerides, N-terminal pro-
brain natriuretic peptide (NT-proBNP), and high-sensitivity C-reactive protein (hs-CRP)
(all p < 0.001). In the KTR group, there were more subjects with diabetes and HbA1c levels
were also higher (p < 0.001). The diet of the KTRs was characterized by lower energy intake
and lower FFQ-derived protein intake compared to healthy controls (p < 0.001). KTRs had
also lower creatinine excretion per 24 h (p < 0.001) (Table 1).
3.2. Urinary CN1 is Inversely Associated with Urinary Carnosine in KTRs
The low excretions per 24h and per mmol creatinine and low concentrations of urinary
carnosine in KTRs prompted us to explore the association between urinary CN1 and
urinary carnosine (Table 2). In KTRs, unadjusted logistic regression analyses revealed that
urinary CN1 concentrations were associated with increased risk for undetectable carnosine
in urine (OR 1.24, 95%CI [1.06–1.45]; p = 0.007). This inverse association was independent
of age and sex, but lost significance after further adjustment for eGFR (OR 0.96, 95%CI
[0.80–1.14]; p = 0.60). No significant associations were found between urinary carnosine
and urinary CN1 in the healthy group (all p > 0.05). Of note, in KTRs, urinary carnosine
excretions were associated with meat intake (St. β = 0.12, p = 0.001).
Table 2. Association of urinary carnosine with urinary CN1 concentrations in KTRs (n = 703).
Variable
Model 1 Model 2 Model 3
OR [95%CI] p-Value OR [95%CI] p-Value OR [95%CI] p-Value
Urinary CN1 concentrations,
µg/L 1.24 [1.06–1.45] 0.007 1.26 [1.07–1.48] 0.006 1.05 [0.88–1.25] 0.60
Sex, male 1.60 [1.12–2.27] 0.009 1.65 [1.14–2.40] 0.008
Age, years 1.04 [1.02–1.05] <0.001 1.03 [1.02–1.05] <0.001
eGFR, ml/min/1.732 0.96 [0.95–0.97] <0.001
Unadjusted and multivariable-adjusted logistic regression analyses were performed to investigate the association of urinary carnosine
with urinary CN1 concentrations in KTRs with adjustment for potential confounders. Urinary CN1 concentrations were log2-transformed
for analyses. Model 1: crude association, Model 2: adjusted for sex and age, Model 3: adjusted as for Model 2 and for eGFR. Odds ratios
and 95% confidence intervals were calculated with urinary carnosine as a dichotomous variable according to its detection cut-off in urine.
Abbreviations: OR: odds ratio, CI: confidence interval, CN1: carnosinase-1, eGFR: estimated glomerular filtration rate, KTRs: kidney
transplant recipients.
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Unadjusted and multivariable-adjusted logistic regression analyses were performed
to investigate the association of urinary carnosine with urinary CN1 concentrations in
KTRs with adjustment for potential confounders. Urinary CN1 concentrations were
log2-transformed for analyses. Model 1: crude association, Model 2: adjusted for sex
and age, Model 3: adjusted as for Model 2 and for eGFR. Odds ratios and 95% confi-
dence intervals were calculated with urinary carnosine as a dichotomous variable ac-
cording to its detection cut-off in urine. Abbreviations: OR: odds ratio, CI: confidence
interval, CN1: carnosinase-1, eGFR: estimated glomerular filtration rate, KTRs: kidney
transplant recipients.
3.3. Urinary CN1 Excretion Is Associated with Urinary Oxidative Stress Markers
The regression coefficients for the association of baseline characteristics and urinary
CN1 excretions in KTRs are shown in Table 3. In univariable analyses, urinary CN1 excre-
tion was positively associated with urinary CN1 concentration, urinary CN1/creatinine
ratio, systolic blood pressure, NT-proBNP, triglycerides, serum creatinine, proteinuria, graft
rejection, FFQ-derived total protein intake, animal protein intake, lactate dehydrogenase
(LDH), urinary sodium excretion, urinary potassium excretion, urinary urea excretion, Ma-
roni formula-derived protein intake, use of antihypertensive medication, use of diuretics,
uMDA excretion, and uL-FABP excretion. Moreover, urinary CN1 excretion was inversely
associated with eGFR, creatinine clearance, and sodium (all p < 0.05) (Table 3, Model 1).
Table 3. Baseline characteristics of KTRs and regression coefficients of the association with urinary CN1 excretions.
Variable
KTR Model 1 Model 2
n = 703 St. β p-Value St. β p-Value
Urinary CN1
CN1 excretion, µg/24h 29.4 [17.4–49.2] - - - -
CN1 concentration, µg/L 12.3 [8.1–20.9] 0.91 <0.001 0.91 <0.001
CN1/creatinine ratio, µg/mmol 2.7 [1.5–4.6] 0.92 <0.001 0.98 <0.001
Demographics
Male, n (%) 399 (57) 0.02 0.56 0.01 0.72
Age, years 53.0 ± 13 0.03 0.47 0.003 0.94
Body composition
Body surface area, m2 1.94 ± 0.22 −0.01 0.71 −0.03 0.46
BMI, kg/m2 26.7 ± 4.8 0.01 0.89 −0.02 0.65
Waist circumference, cm 98 ± 15 0.003 0.94 −0.05 0.17
Lifestyle
Current smoker, n (%) 83 (12) 0.016 0.89 −0.001 0.98
Alcohol intake, g/24h 2.6 [0.03–11.1] −0.02 0.56 −0.01 0.78
Cardiovascular
Systolic blood pressure, mmHg 136 ± 17.5 0.09 0.02 0.07 0.09
Diastolic blood pressure, mmHg 83 ± 11 0.002 0.96 −0.01 0.91
Heart rate, bpm 69 ± 12 0.03 0.49 0.03 0.47
NT-proBNP, ng/L 255 [108–625] 0.21 <0.001 0.13 0.01
Hypertension, n (%) 620 (88) 0.06 0.13 0.04 0.22
Cardiovascular history
CVA and/or TIA, n (%) 41 (6) −0.01 0.77 −0.02 0.60
Myocardial infarction, n (%) 35 (5) −0.004 0.91 −0.01 0.66
Cardiovascular intervention, n (%) 68 (10) 0.07 0.05 0.05 0.16
Lipids
Total cholesterol, mmol/L 5.1 ± 1.1 0.07 0.06 0.05 0.18
HDL cholesterol, mmol/L 1.4 ± 0.5 0.06 0.13 0.11 0.006
LDL cholesterol, mmol/L 3.0 ± 0.9 0.05 0.16 0.04 0.33
Triglycerides, mmol/L 1.7 [1.3–2.3] 0.08 0.04 0.02 0.63
Glucose homeostasis
Diabetes mellitus, n (%) 168 (24) 0.06 0.11 0.05 0.18
Glucose mmol/L 5.3 [4.8–6.0] 0.0001 0.99 0.01 0.84
HbA1c, mmol/mol 41.9 ± 8.9 0.03 0.48 0.03 0.42
Renal function
Serum creatinine, µmol/L 125 [99–160] 0.20 <0.001 −0.02 0.83
eGFR, ml/min/1.73 m2 45.1 ± 18.7 −0.24 <0.001 −0.24 <0.001
Creatinine clearance, mL/min 66 ± 27 −0.12 0.002 −0.19 0.002
Proteinuria, n (%) 157 (22) 0.43 <0.001 0.40 <0.001
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Table 3. Cont.
Variable
KTR Model 1 Model 2
n = 703 St. β p-Value St. β p-Value
Transplantation related
Dialysis vintage, months 27 [10–51] 0.02 0.54 0.01 0.80
Time since transplantation, years 5.4 [1.9–12.0] 0.03 0.44 0.05 0.23
Transplantation up to baseline, n (%) 0.05 0.16 0.04 0.24
First transplantation 633 (90)
Re-transplantation 69 (10)
Age donor, years 43 ± 15.4 0.004 0.92 −0.07 0.07
Sex donor, n (% male) 356 (51) −0.04 0.30 −0.07 0.06
Donor type, living, n (%) 239 (34) −0.04 0.30 −0.015 0.71
Cold ischemia time, hours 15 [3–21] 0.03 0.41 0.010 0.79
Warm ischemia, minutes 40 [33–50] −0.02 0.63 −0.03 0.44
Calcineurin inhibitors, n (%) 381 (56) 0.03 0.52 −0.04 0.29
Proliferator inhibitor, n (%) 567 (84) −0.07 0.09 −0.03 0.40
Prednisolone dosage, n (%) 0.05 0.21 0.05 0.18
≤7.5 mg/24 h 284 (40)
<7.5 mg/24 h 419 (60)
HLA-I n (%) 106 (15) 0.03 0.44 0.004 0.92
HLA-II n (%) 121 (17) 0.04 0.28 0.01 0.76
Graft rejection up to baseline, n (%) 188 (27) 0.08 0.04 0.05 0.20
Post-transplant diabetes mellitus 131 (19) 0.04 0.34 0.03 0.44
Delayed graft function 52 (7) 0.0001 0.99 −0.03 0.44
Dietary intake patterns
Energy intake, kcal/24 h 2170 ± 639 −0.05 0.26 −0.02 0.62
Total protein intake, g/24 h 82 ± 12 0.10 0.01 0.12 0.004
Plant protein intake, g/24 h 31 ± 6 0.04 0.37 0.07 0.12
Animal protein intake, g/24 h 51 ± 13 0.08 0.04 0.08 0.05
Meat intake, g/24 h 95 [74–116] 0.01 0.28 0.01 0.26
Serum parameters
LDH, U/L 198 [170–232] 0.11 0.005 0.06 0.15
Sodium, mmol/L 141 ± 2.8 −0.14 <0.001 −0.12 0.001
Potassium, mmol/L 4.0 ± 0.5 0.037 0.335 −0.040 0.314
Urinary parameters
Sodium excretion, mmol/24 h 146 [114–190] 0.10 0.01 0.14 <0.001
Potassium excretion, mmol/24 h 70.1 [ 55.4–87.2] 0.13 < 0.001 0.19 <0.001
Urea excretion, mmol/24 h 384 [308–456] 0.13 0.001 0.19 <0.001
Maroni protein intake, g/kg bw/24 h 85.3 ± 20.6 0.12 0.003 0.18 <0.001
Creatinine excretion, µmol/24 h 11.6 ± 3.4 0.04 0.30 0.12 0.01
Medication use, n (%)
RAAS blockage 341 (49) 0.03 0.45 0.01 0.90
Antihypertensives 620 (88) 0.11 0.003 0.07 0.08
Diuretic 285 (41) 0.10 0.008 0.03 0.39
Oxidative stress and inflammation
hsCRP, mg/L 1.6 [0.7–4.6] 0.04 0.27 0.02 0.68
uMDA excretion, µmol/24 h 9.7 [5.8–15.7] 0.11 0.003 0.11 0.003
Plasma MDA, µmol/L 2.5 [1.9–3.7] −0.04 0.27 −0.02 0.52
uL-FABP excretion, µg/24 h 2.1 [0.9–7.4] 0.29 <0.001 0.24 <0.001
Primary kidney disease
Primary glomerular disease 198 (28) 0.05 0.20 0.05 0.18
Glomerulonephritis 54 (8) −0.03 0.51 −0.02 0.58
Tubulointerstitial disease 83 (12) 0.002 0.97 0.03 0.43
Polycystic renal disease 146 (21) −0.04 0.30 −0.07 0.05
Dysplasia and hypoplasia 28 (4) 0.04 0.36 0.05 0.21
Renovascular disease 40 (6) −0.02 0.63 −0.02 0.54
Diabetic nephropathy 36 (5) 0.04 0.28 0.02 0.57
Model 1: crude association, Model 2: crude with adjustment for age, sex, and eGFR. Urinary CN1 was log2-transformed for analysis.
Regression coefficients are given as standardized beta values (St. β). Dietary intake was adjusted for energy intake through the residual
method. Abbreviations: BMI: body mass index, NT-proBNP: N-terminal pro-brain natriuretic peptide, CVA: cerebrovascular accident,
TIA: transient ischemic attack, HDL: high-density lipoprotein, LDL: low-density lipoprotein, HLA: human leukocyte antigen, eGFR:
estimated glomerular filtration rate, LDH: lactate dehydrogenase, RAAS: renin–angiotensin–aldosterone system, hsCRP: high-sensitivity
C-reactive protein, uMDA: urinary malondialdehyde, uL-FABP: urinary liver-type fatty acid-binding protein.
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The adjustment for age, sex, and eGFR revealed an association of urinary CN1 excre-
tion with HDL cholesterol and urinary creatinine excretion. In contrast, the association of
urinary CN1 excretion with triglycerides, serum creatinine, graft rejection, animal protein
intake, LDH, use of diuretics, and antihypertensive medication was no longer significant
after adjustments (all p > 0.05).
Furthermore, adjustment for age, sex, and eGFR strengthened the association of
urinary CN1 excretion with creatinine clearance, FFQ-derived protein intake, urinary
sodium excretion, urinary potassium excretion, urinary urea excretion, and Maroni formula
derived protein intake (all p < 0.05). The associations of urinary CN1 excretion with NT-
proBNP, proteinuria, sodium, and uL-FABP excretion weakened, yet remained significant
after adjustment for age, sex, and eGFR (Table 3, Model 2).
3.4. Urinary CN1 Is Associated with High Risk of Graft Failure in KTRs
During median follow-up of 5.3 [4.5–6.0] years, 84 (12%) KTRs developed graft failure.
Of these, 62 (74%) developed chronic rejection, and eight (10%) had recurrence of the
primary disease. KTRs who experienced graft failure had higher median urinary CN1
excretions (42.2 [27.9–92.6] µg/24 h versus 27.9 [16.0–45.2] µg/24 h; p < 0.001) compared to
KTRs with preserved renal grafts. This was also the case for urinary CN1 concentrations
(21.7 [13.8–36.5] µg/L versus 11.7 [7.8–19.1] µg/L; p < 0.001) and urinary CN1/creatinine
ratios (4.5 [2.4–8.7] µg/mmol versus 2.5 [1.4–4.2] µg/mmol; p < 0.001). In line with
this, lower urinary carnosine excretions were found in KTRs experiencing graft failure
(23.5 [17.8–27.1] µmol/24 h versus 27.1 [22.1–34.4] µmol/24h; p < 0.001) in comparison to
KTRs with preserved renal grafts. Similar differences were found for urinary carnosine
concentrations and urinary carnosine/creatinine ratios (all p < 0.001).
Model 1: crude association, Model 2: crude with adjustment for age, sex, and eGFR.
Urinary CN1 was log2-transformed for analysis. Regression coefficients are given as
standardized beta values (St. β). Dietary intake was adjusted for energy intake through
the residual method. Abbreviations: BMI: body mass index, NT-proBNP: N-terminal
pro-brain natriuretic peptide, CVA: cerebrovascular accident, TIA: transient ischemic
attack, HDL: high-density lipoprotein, LDL: low-density lipoprotein, HLA: human leuko-
cyte antigen, eGFR: estimated glomerular filtration rate, LDH: lactate dehydrogenase,
RAAS: renin–angiotensin–aldosterone system, hsCRP: high-sensitivity C-reactive protein,
uMDA: urinary malondialdehyde, uL-FABP: urinary liver-type fatty acid-binding protein.
Prospective analyses of the association between urinary CN1 excretions, CN1 con-
centrations, and CN1/creatinine ratios with death-censored graft failure are shown in
Table 4. The proportional hazard assumption was checked for urinary CN1 excretions,
concentrations, and creatinine ratios (all p > 0.05). Cox regression analyses revealed an
association of log2 urinary CN1 excretions (HR 1.73, 95%CI [1.44–2.08]; p < 0.001), log2
urinary CN1 concentrations (HR 2.05, 95%CI [1.69–2.49]; p < 0.001), and log2 urinary
CN1/creatinine ratio (HR 1.76, 95%CI [1.48–2.09]; p < 0.001) with graft failure (Model 1).
These associations remained materially unchanged after adjustment for age, sex, and BMI
(Model 2). After cumulative adjustment for eGFR and proteinuria, the associations of
urinary CN1 excretion (HR 1.24, 95%CI [1.03–1.51]; p = 0.026), urinary CN1 concentration
(HR 1.36, 95%CI [1.11–1.67]; p = 0.003), and urinary CN1/creatinine ratio (HR 1.32, 95%
CI [1.09–1.61]; p = 0.005) with graft failure somewhat weakened, though they remained
significant (Model 3). Moreover, these associations remained independent of additional
adjustment for cardiovascular risk factors (Model 4), for transplantation-related parameters
(Model 5), for transplantation complications (Model 6), and for urinary parameters (Model
7) (Table 4). No significant interactions with age, sex, BMI, eGFR, proteinuria, and urinary
urea excretions were found for the associations of urinary CN1 with graft failure (p > 0.05).
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HR [95%CI] p-Value HR [95%CI] p-Value HR [95%CI] p-Value
Model 1 1.73 [1.44–2.08] <0.001 2.05 [1.69–2.49] <0.001 1.76 [1.48–2.09] <0.001
Model 2 1.74 [1.44–2.09] <0.001 2.05 [1.69–2.49] <0.001 1.85 [1.55–2.21] <0.001
Model 3 1.24 [1.03–1.51] 0.026 1.36 [1.11–1.67] 0.003 1.32 [1.09–1.61] 0.005
Model 4 1.32 [1.06–1.61] 0.011 1.43 [1.15–1.78] 0.002 1.39 [1.13–1.72] 0.002
Model 5 1.24 [1.01–1.52] 0.042 1.39 [1.12–1.72] 0.003 1.31 [1.06–1.60] 0.001
Model 6 1.23 [1.01–1.50] 0.037 1.34 [1.09–1.65] 0.005 1.31 [1.07–1.59] 0.008
Model 7 1.31 [1.08–1.60] 0.008 1.37 [1.12–1.69] 0.003 1.32 [1.09–1.61] 0.005
Cox regression analyses were performed to assess the associations of log2-transformed urinary CN1 excretion, urinary CN1 concentration,
and urinary CN1 creatinine ratio with death-censored graft failure (number of events = 84) in KTRs (n = 703). Model 1: crude associations.
Multivariable Model 2: adjusted for basic confounders (age, sex, and BMI). Multivariable Model 3 as for Model 2 with additional adjustment
for eGFR and proteinuria. Subsequently, additive adjustments were performed based on variables already adjusted for in Model 3.
Model 4: further adjustment for cardiovascular risk factors (systolic blood pressure, HDL cholesterol, triglycerides, antihypertensive
medication usage, diabetes mellitus, and medical history of cardiovascular intervention). Model 5 involved further adjustment for
transplantation-related factors (dialysis vintage, time from transplantation to baseline, donor type, need for re-transplantation up to
baseline, and use of calcineurin inhibitors). Model 6: further adjusted for post-transplantation complications (delayed graft function, graft
rejection, and post-transplant diabetes mellitus) and Model 7 involved further adjustment for urinary parameters (urinary sodium, urinary
potassium, and urinary urea). Abbreviations: CN1: carnosinase-1, HR: hazard ratio, CI: confidence interval, eGFR: estimated glomerular
filtration rate, HDL: high-density lipoprotein.
Cox regression analyses were performed to assess the associations of log2-transformed
urinary CN1 excretion, urinary CN1 concentration, and urinary CN1 creatinine ratio with
death-censored graft failure (number of events = 84) in KTRs (n = 703). Model 1: crude
associations. Multivariable Model 2: adjusted for basic confounders (age, sex, and BMI).
Multivariable Model 3 as for Model 2 with additional adjustment for eGFR and proteinuria.
Subsequently, additive adjustments were performed based on variables already adjusted
for in Model 3. Model 4: further adjustment for cardiovascular risk factors (systolic blood
pressure, HDL cholesterol, triglycerides, antihypertensive medication usage, diabetes
mellitus, and medical history of cardiovascular intervention). Model 5 involved further
adjustment for transplantation-related factors (dialysis vintage, time from transplantation
to baseline, donor type, need for re-transplantation up to baseline, and use of calcineurin
inhibitors). Model 6: further adjusted for post-transplantation complications (delayed
graft function, graft rejection, and post-transplant diabetes mellitus) and Model 7 involved
further adjustment for urinary parameters (urinary sodium, urinary potassium, and urinary
urea). Abbreviations: CN1: carnosinase-1, HR: hazard ratio, CI: confidence interval, eGFR:
estimated glomerular filtration rate, HDL: high-density lipoprotein.
The associations of log2-transformed urinary CN1 excretion, urinary CN1 concentra-
tion, and urinary CN1/creatinine ratio as continuous variables with graft failure are shown
in Figure 1.
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Figure 1. Urinary CN1 and Risk of Graft Failure in KTR. Association of urinary CN1 with death-censored graft failure in
KTRs. Continuous association of urinary CN1 excretion A, urinary CN1 concentration B, and urinary CN1/creatinine ratio C
with death-censored graft failure in KTRs. Urinary CN1 excretion, urinary CN1 concentrations, and urinary CN1/creatinine
ratios were log2 -transformed for prospective analyses. The histograms depict the distribution. The black line shows the
adjusted hazard ratio (HR), and the gray areas correspond to the 95% confidence interval (CI). X-axis represents urinary CN1
excretion and concentration or creatinine ratios, and the y-axis represents the estimated hazard ratio relative to the mean
urinary CN1 excretion, concentration, or creatinine ratio as reference values. The adjusted association was adjusted for age,
sex, BMI, eGFR, and proteinuria (Model 3). p values were 0.02, 0.003, and 0.005, respectively. Urinary CN1 concentration
values below detection level are not shown. Abbreviations: HR: hazard ratio, CN1: carnosinase-1.
4. Discussion
The key findings of the present study are as follows: urinary carnosine levels are
depleted in KTRs in comparison to healthy controls. Secondly, urinary CN1 concentra-
tions are inversely associated with urinary carnosine in the KTR population, although
this inverse association appears to be mediated by renal function. Thirdly, high urinary
CN1 is independently and positively associated with risk of late graft failure in KTRs.
These observations hold true for the analyses of urinary excretions, concentrations, and
creatinine/ratios.
Although primarily synthesized in the liver, CN1 is also expressed in the kidney
[6,8,41]. Like other secreted proteins, CN1 contains a signal peptide which directs the
protein to the secretory pathway [42]. While serum CN1 concentrations depend mostly
on the amount of CN1 synthesized by the liver, urinary CN1 concentrations in healthy
individuals may reflect local renal CN1 synthesis as the dimeric CN1 protein is too large
(130 kD) to cross the glomerular filtration barrier (cut-off ~50 kD) [43]. Under circumstances
of an impaired glomerular filtration barrier, CN1 might be filtered, thereby reaching the
urinary compartment [23,24]. Of note, in our previous studies and in the current one, we did
not detect any CN1 enzymatic activity in urine [23,24]. Owing to the urine-concentrating
capacity of the kidney, which is based on the maintenance of a very high urea concentration
gradient, interstitial urea concentrations in mammalian renal cells at some segments of
the nephron (inner medulla) can reach very high levels (>1.0 M) [44,45]. In addition, urea
concentrations are often very high in urine (~0.28 M) [46]. These high intracellular and
urine urea concentrations may denature proteins by affecting the secondary and tertiary
structure of proteins, thereby altering their enzymatic function. This might explain the
absence of CN1 enzymatic activity in the urine. Yet, formal proof of this phenomenon is
currently lacking and could be assessed in future studies.
Although urinary CN1 levels did not differ between the healthy group and the KTRs,
an inverse association between urinary CN1 concentrations and urinary carnosine was
found in the latter group. This finding might indirectly raise the question whether CN1
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activity could be enhanced in KTRs. This speculation is further supported by the finding
that the relative proportion of urinary carnosine below the detection limit was higher
in KTRs (66% versus 37%; p < 0.001) (Table 1). Moreover, as under conditions of high
oxidative stress, e.g., diabetes and aging, the efficiency of CN1 in cleaving carnosine is
increased [47–49], this might also be the case for KTRs, who have been shown to inevitably
experience increased oxidative stress [50]. In line with this, our study also disclosed a
positive and strong association between the oxidative stress markers, i.e., uMDA and
L-FABP, with urinary CN1 excretion, making it likely that overall CN1 activity is higher in
KTRs. In the study of Zhou et al., an association between low serum carnosine and high
serum CN1 concentrations and enzymatic activity was found exclusively in patients with
diabetes and severe renal damage. This was accompanied by a positive association between
serum CN1 concentrations and the renal expression of oxidative stress markers, i.e., 4-HNE
(4-hydroxynonenal) and 8-OHdG (8-hydroxynonenal) [51]. The findings from this study
support the hypothesis that carnosine depletion resulting from high CN1 expression might
be associated with increased renal damage.
Carnosine is predominantly present in skeletal muscle. As a dietary source, it is
abundantly present in meat, with the highest concentrations being found in beef, mutton,
pork, and to a lesser extent in poultry [14,52]. It is unlikely that the difference in urinary
carnosine levels was due to differences in total meat or red meat intake, as these were
similar among KTRs and the healthy group. Since “The Dutch Food Composition Table”
does not include information on carnosine content, the exact contribution of the diet
to urinary carnosine could not be addressed herein. Furthermore, it might also be the
case that the relative contribution of meat intake to urinary carnosine levels varies under
healthy and kidney disease conditions. Being freely filtered at the glomerulus, carnosine is
partially reabsorbed by high-affinity oligopeptide transporters PEPT1 and PEPT2 in the
proximal tubules [53] where it might exert beneficial reno-protective effects [54]. Although
the relation between carnosine and kidney function is not well characterized, it is likely
that renal clearance of carnosine might be affected by kidney function. Consequently,
circulating carnosine in patients with impaired kidney function might be hydrolyzed to a
large extent by serum CN1 before reaching the kidney. This assumption is supported by
the finding that the inverse association of CN1 and carnosine disappeared after adjustment
for eGFR. Future in vitro and in vivo studies manipulating carnosine and CN1 levels
are warranted to further establish a potential link between high CN1 activity, low renal
carnosine concentrations, oxidative stress, and renal damage.
We have previously shown in cross-sectional studies that urinary CN1 levels are
positively associated with albuminuria and inversely with kidney function [23,24]. In
agreement with this, the current study also shows that urinary CN1 excretion is likely
affected by renal function, reflected by the strong association of urinary CN1 with eGFR and
proteinuria. Furthermore, our findings demonstrate that urinary CN1 is associated with
risk of graft failure in KTRs. This association was found to be independent of proteinuria
and renal function. It is noteworthy that adjustments for previously described determinants
of graft loss [55] caused a slight weakening, leaving a significant association of urinary
CN1 with graft failure. Along these lines, previous studies have suggested that high CN1
levels are a risk factor for the development of nephropathy in patients with diabetes [6].
Despite the high impact of modern immunosuppressive and overall supportive ther-
apy, patients undergoing kidney transplantation have limited long-term graft survival [56].
One of the contributing mechanisms to renal dysfunction is oxidative stress, reflected
by high levels of reactive oxygen species (ROS) and inflammatory markers [57,58]. The
assumption that CN1 enzymatic activity might be higher in KTRs as compared to healthy
controls is supported by previous reports suggesting that oxidative stress enhances CN1
activity [47,48]. Moreover, urinary CN1 excretions are higher in KTRs who experienced
graft failure, which together with a presumably increased CN1 activity in renal tissue may
have a large impact on urinary carnosine levels. Hence, high urinary CN1 might render
the kidney vulnerable to oxidative and carbonyl stress. The significance of our study lies
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in the fact that urinary CN1 could potentially be a biomarker of the overall inflammatory
state of the kidney through carnosine availability. Future studies in other populations at
risk of an inflammatory milieu are warranted.
Carnosine is generally considered as a bioactive food component with potential
health benefits. Several physiological roles have been ascribed to carnosine, including high
intracellular pH buffer capacity and protection against oxidative and carbonyl stress [59–61].
Additional potential mechanisms of the action of carnosine include an overall lowering
of chronic low-grade inflammation and acceleration of wound healing by promoting
the expression of growth factors and cytokines involved in reparative processes [62]. In
animal models of renal ischemia reperfusion, carnosine treatment was associated with
attenuation of ischemia reperfusion-induced renal dysfunction [63,64]. Furthermore, in a
recent randomized control trial, oral carnosine supplementation resulted in a significant
improvement of oxidative stress, glycemic control, and renal function in pediatric patients
with diabetic nephropathy [65]. Whether carnosine supplementation in KTRs might have
beneficial effects remains to be addressed in future interventional studies. Alternatively,
the use of selective CN1 inhibitors [66] or carnosine analogs resistant to CN1 activity [67]
might be considered as these compounds have shown promising results in preclinical
studies in diabetic models.
Although our study has several key strengths, e.g., large sample size and a comprehen-
sive collection of parameters that enables adjustment for multiple potential confounders,
this study suffers from the usual inherent limitations of observational studies, which do
not allow for establishing causative links or underlying mechanisms. Furthermore, we did
not investigate the association of urinary carnosine with key inflammatory markers such as
IL-6 and TNF-α and this could be assessed in future studies. In addition, the population of
this study consisted of Caucasian subjects, which calls for caution in case of extrapolation
to other ethnicities.
5. Conclusions
In conclusion, high urinary CN1 levels are associated with low graft survival in KTRs,
who in turn have low urinary carnosine levels. An adverse impact of high CN1 activity
seems very likely, since CN1 regulates carnosine and other histidine-containing dipeptides
directly involved in tissue protection. As a result, low carnosine might render the kidney
vulnerable to oxidative and carbonyl stress. Urinary CN1 could potentially be a marker of
the overall inflammatory state of the kidney.
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Appendix A
Appendix A.1 Carnosinase-1 Determination in Urine by ELISA
Highly absorbent microtiter plates (Greiner, Labortechnick, Frickenhausen, Germany)
were coated overnight with goat polyclonal antihuman CN1 (1 µg/mL) (R&D, Wiesbaden,
Germany). Samples were tested undiluted or in a 1:2 dilution factor. As a standard
curve, serial dilutions (250–3.9 ng/mL) of mouse CN1 recombinant [His-tag] protein
(Sino Biological, Beijing, China) were used. CN1 concentrations were interpolated in
the linear range of the dilution curve, with a lower detection limit of 4 ng/mL. After
washing, rabbit polyclonal antibody (Atlas, Abcam plc, Cambridge, UK) was added for
a 1h incubation followed by goat anti-rabbit IgG antibody conjugated to horseradish
peroxidase (Thermo Scientific, Eugene, Oregon, USA). BM blue peroxidase substrate
(Roche Diagnostics, Mannheim, Germany) was added as a chromogen, and the reaction was
stopped by the addition of 1 M H2SO4. The plates were directly read at 450 nm absorbance.
Concentrations below the detection limit were set as 4 ng/mL. Urinary CN1 excretions were
obtained by multiplying 24h urine volume (liters). Intra-assay coefficients of variability
were 2.7% and 1.3% for concentrations of 21 ng/mL and 6 ng/mL, respectively.
Appendix A.2 Amino Acid Profiling with Liquid Chromatography Isotope Dilution
Mass Spectrometry
Samples were derivatized using the AccQTag derivatization reagent according to the
manufacturer’s protocol (Waters Corporation, Milford, MA, USA) and separated using
a Phenomenex Synergi™ column (4 µm Polar-RP 80 Å, 150 × 3 mm). Carnosine was
detected using positive-ion electrospray ionization in multiple reaction-monitoring mode,
using 13C6, 15N3-histidine as an internal standard. Data were analyzed using MultiQuant
MD 3.0.2 (Sciex). Inter-assay precision was monitored using a urine pool sample. The
inter-assay precisions were 7% at 22.7 µmol/L and 11% at 13.6 µmol/L. The upper limit of
detection was 1200 µmol/L and values above 1200 µmol/L were reported as 1201 µmol/L.
The lower limit of detection was 10 µmol/L and concentrations below were reported
as 9.9 µmol/L. Urinary carnosine excretions were obtained after multiplying carnosine
concentration (µmol/L) by 24 h urine volume.
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